Genes and environments in schizophrenia: The different pieces of a manifold puzzle

Neuroscience and Biobehavioral Reviews

Volumn 37, Issue 10, 2013, Pages 2424-2437

  Réthelyi, János M ^a   Benkovits, Judit ^a   Bitter, István ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

CNV; Environment; Gene environment interaction; Genetic; In vitro disease modeling; Next generation sequencing; Schizophrenia; SNP

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CANNABIS; DEXTRO AMINO ACID OXIDASE ACTIVATOR; DOPAMINE TRANSPORTER; DYSBINDIN; ENZYME ACTIVATOR; GLUTAMATE RECEPTOR 3; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN; MATRIX METALLOPROTEINASE 16; MICRORNA; MICRORNA 137; NEU DIFFERENTIATION FACTOR; NEUROGRANIN; PROTEIN KINASE B; RGS4 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR 4; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ALLELE; CANNABIS ADDICTION; COPY NUMBER VARIATION; CSMD1 GENE; DAOA GENE; DISEASE ASSOCIATION; DISEASE MODEL; DISEASE SEVERITY; DTNBP1 GENE; ENVIRONMENTAL FACTOR; GENE; GENE MUTATION; GENE TECHNOLOGY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HEREDITY; HUMAN; INTRAUTERINE INFECTION; MALADJUSTMENT; MHC GENE; MMP16 GENE; NGRN GENE; NONHUMAN; NRG1 GENE; PATHOGENESIS; PHENOTYPIC VARIATION; PREGNANCY COMPLICATION; PREVALENCE; PRIORITY JOURNAL; PSYCHOTRAUMA; REVIEW; RGS4 GENE; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIAL DISCRIMINATION; SYMPTOMATOLOGY; URBANIZATION; VRK2 GENE; ZNF804A GENE;

CNV; ENVIRONMENT; GENE-ENVIRONMENT INTERACTION; GENETIC; IN VITRO DISEASE MODELING; NEXT GENERATION SEQUENCING; SCHIZOPHRENIA; SNP;

ENVIRONMENT; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; RISK FACTORS; SCHIZOPHRENIA;

EID: 84890144483     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2013.04.010     Document Type: Review

References (148)

1. Alemany S., Goldberg X., van Winkel R., Gasto C., Peralta V., Fananas L. Childhood adversity and psychosis: examining whether the association is due to genetic confounding using a monozygotic twin differences approach. Eur. Psychiatry 2012, 10.1016/j.eurpsy.2012.03.001.
2. Allen N.C., Bagade S., McQueen M.B., Ioannidis J.P., Kavvoura F.K., Khoury M.J., Tanzi R.E., Bertram L. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat. Genet. 2008, 40:827-834.
3. Arguello P.A., Gogos J.A. Modeling madness in mice: one piece at a time. Neuron 2006, 52:179-196.
4. Arseneault L., Cannon M., Fisher H.L., Polanczyk G., Moffitt T.E., Caspi A. Childhood trauma and children's emerging psychotic symptoms: a genetically sensitive longitudinal cohort study. Am. J. Psychiatry 2011, 168:65-72.
5. Arseneault L., Cannon M., Poulton R., Murray R., Caspi A., Moffitt T.E. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002, 325:1212-1213.
6. Ayhan Y., Sawa A., Ross C.A., Pletnikov M.V. Animal models of gene-environment interactions in schizophrenia. Behav. Brain Res. 2009, 204:274-281.
7. Bakker S.C., Hoogendoorn M.L., Hendriks J., Verzijlbergen K., Caron S., Verduijn W., Selten J.P., Pearson P.L., Kahn R.S., Sinke R.J. The PIP5K2A and RGS4 genes are differentially associated with deficit and non-deficit schizophrenia. Genes Brain Behav. 2007, 6:113-119.
8. Bakker S.C., Hoogendoorn M.L., Selten J.P., Verduijn W., Pearson P.L., Sinke R.J., Kahn R.S. Neuregulin 1: genetic support for schizophrenia subtypes. Mol. Psychiatry 2004, 9:1061-1063.
9. Bassett A.S., Costain G., Fung W.L., Russell K.J., Pierce L., Kapadia R., Carter R.F., Chow E.W., Forsythe P.J. Clinically detectable copy number variations in a Canadian catchment population of schizophrenia. J. Psychiatr. Res. 2010, 44:1005-1009.
10. Bassett A.S., Marshall C.R., Lionel A.C., Chow E.W., Scherer S.W. Copy number variations and risk for schizophrenia in 22q11.2 deletion syndrome. Hum. Mol. Genet. 2008, 17:4045-4053.
11. Bassett A.S., Scherer S.W., Brzustowicz L.M. Copy number variations in schizophrenia: critical review and new perspectives on concepts of genetics and disease. Am. J. Psychiatry 2010, 167:899-914.
12. Beaulieu J.M., Sotnikova T.D., Yao W.D., Kockeritz L., Woodgett J.R., Gainetdinov R.R., Caron M.G. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:5099-5104.
13. Bhattacharyya S., Atakan Z., Martin-Santos R., Crippa J.A., Kambeitz J., Prata D., Williams S., Brammer M., Collier D.A., McGuire P.K. Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of delta-9-tetrahydrocannabinol on midbrain and striatal function. Mol. Psychiatry 2012, 17:1152-1155.
14. Bilder R.M., Howe A., Novak N., Sabb F.W., Parker D.S. The genetics of cognitive impairment in schizophrenia: a phenomic perspective. Trends Cogn. Sci. 2011, 15:428-435.
15. Brandon N.J., Millar J.K., Korth C., Sive H., Singh K.K., Sawa A. Understanding the role of DISC1 in psychiatric disease and during normal development. J. Neurosci. 2009, 29:12768-12775.
16. Brennand K.J., Simone A., Jou J., Gelboin-Burkhart C., Tran N., Sangar S., Li Y., Mu Y., Chen G., Yu D., McCarthy S., Sebat J., Gage F.H. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011, 473:221-225.
17. Brown A.S. The environment and susceptibility to schizophrenia. Prog. Neurobiol. 2011, 93:23-58.
18. Burdick K.E., Goldberg T.E., Funke B., Bates J.A., Lencz T., Kucherlapati R., Malhotra A.K. DTNBP1 genotype influences cognitive decline in schizophrenia. Schizophr. Res. 2007, 89:169-172.
19. Cahn W., Rais M., Stigter F.P., van Haren N.E., Caspers E., Hulshoff Pol H.E., Xu Z., Schnack H.G., Kahn R.S. Psychosis and brain volume changes during the first five years of schizophrenia. Eur. Neuropsychopharmacol. 2009, 19:147-151.
20. Cantor-Graae E., Selten J.P. Schizophrenia and migration: a meta-analysis and review. Am. J. Psychiatry 2005, 162:12-24.
21. Caspi A., McClay J., Moffitt T.E., Mill J., Martin J., Craig I.W., Taylor A., Poulton R. Role of genotype in the cycle of violence in maltreated children. Science 2002, 297:851-854.
22. Caspi A., Moffitt T.E. Gene-environment interactions in psychiatry: joining forces with neuroscience. Nat. Rev. Neurosci. 2006, 7:583-590.
23. Caspi A., Moffitt T.E., Cannon M., McClay J., Murray R., Harrington H., Taylor A., Arseneault L., Williams B., Braithwaite A., Poulton R., Craig I.W. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene×environment interaction. Biol. Psychiatry 2005, 57:1117-1127.
24. Caspi A., Sugden K., Moffitt T.E., Taylor A., Craig I.W., Harrington H., McClay J., Mill J., Martin J., Braithwaite A., Poulton R. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003, 301:386-389.
25. Caspi A., Williams B., Kim-Cohen J., Craig I.W., Milne B.J., Poulton R., Schalkwyk L.C., Taylor A., Werts H., Moffitt T.E. Moderation of breastfeeding effects on the IQ by genetic variation in fatty acid metabolism. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:18860-18865.
26. Chen J., Lipska B.K., Weinberger D.R. Genetic mouse models of schizophrenia: from hypothesis-based to susceptibility gene-based models. Biol. Psychiatry 2006, 59:1180-1188.
27. Chiang C.H., Su Y., Wen Z., Yoritomo N., Ross C.A., Margolis R.L., Song H., Ming G.L. Integration-free induced pluripotent stem cells derived from schizophrenia patients with a DISC1 mutation. Mol. Psychiatry 2011, 16:358-360.
28. Clarke M.C., Tanskanen A., Huttunen M., Whittaker J.C., Cannon M. Evidence for an interaction between familial liability and prenatal exposure to infection in the causation of schizophrenia. Am. J. Psychiatry 2009, 166:1025-1030.
29. Corvin A., Craddock N., Sullivan P.F. Genome-wide association studies: a primer. Psychol. Med. 2010, 40:1063-1077.
30. Costas J., Sanjuan J., Ramos-Rios R., Paz E., Agra S., Tolosa A., Paramo M., Brenlla J., Arrojo M. Interaction between COMT haplotypes and cannabis in schizophrenia: a case-only study in two samples from Spain. Schizophr. Res. 2011, 127:22-27.
31. Crowley J.J., Hilliard C.E., Kim Y., Morgan M.B., Lewis L.R., Muzny D.M., Hawes A.C., Sabo A., Wheeler D.A., Lieberman J.A., Sullivan P.F., Gibbs R.A. Deep resequencing and association analysis of schizophrenia candidate genes. Mol. Psychiatry 2013, 18:138-140.
32. Dempster E.L., Pidsley R., Schalkwyk L.C., Owens S., Georgiades A., Kane F., Kalidindi S., Picchioni M., Kravariti E., Toulopoulou T., Murray R.M., Mill J. Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder. Hum. Mol. Genet. 2011, 20:4786-4796.
33. Dragt S., Nieman D.H., Veltman D., Becker H.E., van de Fliert R., de Haan L., Linszen D.H. Environmental factors and social adjustment as predictors of a first psychosis in subjects at ultra high risk. Schizophr. Res. 2011, 125:69-76.
34. Dutt A., McDonald C., Dempster E., Prata D., Shaikh M., Williams I., Schulze K., Marshall N., Walshe M., Allin M., Collier D., Murray R., Bramon E. The effect of COMT, BDNF, 5-HTT, NRG1 and DTNBP1 genes on hippocampal and lateral ventricular volume in psychosis. Psychol. Med. 2009, 39:1783-1797.
35. Egan M.F., Goldberg T.E., Kolachana B.S., Callicott J.H., Mazzanti C.M., Straub R.E., Goldman D., Weinberger D.R. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:6917-6922.
36. Engel G.L. The need for a new medical model: a challenge for biomedicine. Science 1977, 196:129-136.
37. Esslinger C., Walter H., Kirsch P., Erk S., Schnell K., Arnold C., Haddad L., Mier D., Opitz von Boberfeld C., Raab K., Witt S.H., Rietschel M., Cichon S., Meyer-Lindenberg A. Neural mechanisms of a genome-wide supported psychosis variant. Science 2009, 324:605.
38. Fett A.K., Viechtbauer W., Dominguez M.D., Penn D.L., van Os J., Krabbendam L. The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neurosci. Biobehav. Rev. 2011, 35:573-588.
39. Fusar-Poli P., Borgwardt S., Bechdolf A., Addington J., Riecher-Rossler A., Schultze-Lutter F., Keshavan M., Wood S., Ruhrmann S., Seidman L.J., Valmaggia L., Cannon T., Velthorst E., De Haan L., Cornblatt B., Bonoldi I., Birchwood M., McGlashan T., Carpenter W., McGorry P., Klosterkotter J., McGuire P., Yung A. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry 2013, 70:107-120.
40. Galton F. English Men of Science: Their Nature and Nurture 1874, Macmillan, London.
41. Gejman P.V., Sanders A.R., Duan J. The role of genetics in the etiology of schizophrenia. Psychiatr. Clin. N. Am. 2010, 33:35-66.
42. Gejman P.V., Sanders A.R., Kendler K.S. Genetics of schizophrenia: new findings and challenges. Annu. Rev. Genomics Hum. Genet. 2011, 12:121-144.
43. Genetic Risk and Outcome in Psychosis (GROUP) Investigators Evidence that familial liability for psychosis is expressed as differential sensitivity to cannabis: an analysis of patient-sibling and sibling-control pairs. Arch. Gen. Psychiatry 2011, 68:138-147.
44. Girard S.L., Gauthier J., Noreau A., Xiong L., Zhou S., Jouan L., Dionne-Laporte A., Spiegelman D., Henrion E., Diallo O., Thibodeau P., Bachand I., Bao J.Y., Tong A.H., Lin C.H., Millet B., Jaafari N., Joober R., Dion P.A., Lok S., Krebs M.O., Rouleau G.A. Increased exonic de novo mutation rate in individuals with schizophrenia. Nat. Genet. 2011, 43:860-863.
45. Green M.J., Cairns M.J., Wu J., Dragovic M., Jablensky A., Tooney P.A., Scott R.J., Carr V.J. Genome-wide supported variant MIR137 and severe negative symptoms predict membership of an impaired cognitive subtype of schizophrenia. Mol. Psychiatry 2012, 10.1038/mp.2013.48.
46. Greenwood T.A., Lazzeroni L.C., Murray S.S., Cadenhead K.S., Calkins M.E., Dobie D.J., Green M.F., Gur R.E., Gur R.C., Hardiman G., Kelsoe J.R., Leonard S., Light G.A., Nuechterlein K.H., Olincy A., Radant A.D., Schork N.J., Seidman L.J., Siever L.J., Silverman J.M., Stone W.S., Swerdlow N.R., Tsuang D.W., Tsuang M.T., Turetsky B.I., Freedman R., Braff D.L. Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am. J. Psychiatry 2011, 168:930-946.
47. Habets P., Marcelis M., Gronenschild E., Drukker M., van Os J. Reduced cortical thickness as an outcome of differential sensitivity to environmental risks in schizophrenia. Biol. Psychiatry 2011, 69:487-494.
48. Hamshere M.L., Walters J.T., Smith R., Richards A.L., Green E., Grozeva D., Jones I., Forty L., Jones L., Gordon-Smith K., Riley B., O'Neill T., Kendler K.S., Sklar P., Purcell S., Kranz J., Morris D., Gill M., Holmans P., Craddock N., Corvin A., Owen M.J., O'Donovan M.C. Genome-wide significant associations in schizophrenia to ITIH3/4, CACNA1C and SDCCAG8, and extensive replication of associations reported by the Schizophrenia PGC. Mol. Psychiatry 2012, 10.1038/mp.2012.89.
49. Henquet C., Krabbendam L., Spauwen J., Kaplan C., Lieb R., Wittchen H.U., van Os J. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2005, 330:11.
50. Henquet C., Murray R., Linszen D., van Os J. The environment and schizophrenia: the role of cannabis use. Schizophr. Bull. 2005, 31:608-612.
51. Henquet C., Rosa A., Delespaul P., Papiol S., Fananas L., van Os J., Myin-Germeys I. COMT ValMet moderation of cannabis-induced psychosis: a momentary assessment study of 'switching on' hallucinations in the flow of daily life. Acta Psychiatr. Scand. 2009, 119:156-160.
52. Henquet C., Rosa A., Krabbendam L., Papiol S., Fananas L., Drukker M., Ramaekers J.G., van Os J. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 2006, 31:2748-2757.
53. Henquet C., Van Os J. The coherence of the evidence linking cannabis with psychosis. Psychol. Med. 2008, 38:461-462. [author reply 462-464].
54. Henquet C., van Os J., Kuepper R., Delespaul P., Smits M., Campo J.A., Myin-Germeys I. Psychosis reactivity to cannabis use in daily life: an experience sampling study. Br. J. Psychiatry 2010, 196:447-453.
55. Ingason A., Rujescu D., Cichon S., Sigurdsson E., Sigmundsson T., Pietilainen O.P., Buizer-Voskamp J.E., Strengman E., Francks C., Muglia P., Gylfason A., Gustafsson O., Olason P.I., Steinberg S., Hansen T., Jakobsen K.D., Rasmussen H.B., Giegling I., Moller H.J., Hartmann A., Crombie C., Fraser G., Walker N., Lonnqvist J., Suvisaari J., Tuulio-Henriksson A., Bramon E., Kiemeney L.A., Franke B., Murray R., Vassos E., Toulopoulou T., Muhleisen T.W., Tosato S., Ruggeri M., Djurovic S., Andreassen O.A., Zhang Z., Werge T., Ophoff R.A., Rietschel M., Nothen M.M., Petursson H., Stefansson H., Peltonen L., Collier D., Stefansson K., St Clair D.M. Copy number variations of chromosome 16p13.1 region associated with schizophrenia. Mol. Psychiatry 2011, 16:17-25.
56. Insel T.R. Rethinking schizophrenia. Nature 2010, 468:187-193.
57. Karayiorgou M., Morris M.A., Morrow B., Shprintzen R.J., Goldberg R., Borrow J., Gos A., Nestadt G., Wolyniec P.S., Lasseter V.K., et al. Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:7612-7616.
58. Keri S., Beniczky S., Kelemen O. Suppression of the P50 evoked response and neuregulin 1-induced AKT phosphorylation in first-episode schizophrenia. Am. J. Psychiatry 2010, 167:444-450.
59. Keri S., Kiss I., Kelemen O. Effects of a neuregulin 1 variant on conversion to schizophrenia and schizophreniform disorder in people at high risk for psychosis. Mol. Psychiatry 2009, 14:118-119.
60. Keri S., Kiss I., Seres I., Kelemen O. A polymorphism of the neuregulin 1 gene (SNP8NRG243177/rs6994992) affects reactivity to expressed emotion in schizophrenia. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2009, 150B:418-420.
61. Kiezun A., Garimella K., Do R., Stitziel N.O., Neale B.M., McLaren P.J., Gupta N., Sklar P., Sullivan P.F., Moran J.L., Hultman C.M., Lichtenstein P., Magnusson P., Lehner T., Shugart Y.Y., Price A.L., de Bakker P.I., Purcell S.M., Sunyaev S.R. Exome sequencing and the genetic basis of complex traits. Nat. Genet. 2012, 44:623-630.
62. Kim Y., Zerwas S., Trace S.E., Sullivan P.F. Schizophrenia genetics: where next?. Schizophr. Bull. 2011, 37:456-463.
63. Kiss I., Kelemen O., Keri S. Decreased peripheral expression of neuregulin 1 in high-risk individuals who later converted to psychosis. Schizophr. Res. 2012, 135:198-199.
64. Kong A., Frigge M.L., Masson G., Besenbacher S., Sulem P., Magnusson G., Gudjonsson S.A., Sigurdsson A., Jonasdottir A., Wong W.S., Sigurdsson G., Walters G.B., Steinberg S., Helgason H., Thorleifsson G., Gudbjartsson D.F., Helgason A., Magnusson O.T., Thorsteinsdottir U., Stefansson K. Rate of de novo mutations and the importance of father's age to disease risk. Nature 2012, 488:471-475.
65. Konings M., Stefanis N., Kuepper R., de Graaf R., Have M.T., van Os J., Bakoula C., Henquet C. Replication in two independent population-based samples that childhood maltreatment and cannabis use synergistically impact on psychosis risk. Psychol. Med. 2011, 1-11.
66. Ku C.S., Naidoo N., Wu M., Soong R. Studying the epigenome using next generation sequencing. J. Med. Genet. 2011, 48:721-730.
67. Kuepper R., van Os J., Lieb R., Wittchen H.U., Henquet C. Do cannabis and urbanicity co-participate in causing psychosis? Evidence from a 10-year follow-up cohort study. Psychol. Med. 2011, 1-9.
68. Kuepper R., van Os J., Lieb R., Wittchen H.U., Hofler M., Henquet C. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ 2011, 342:d738.
69. Kwon E., Wang W., Tsai L.H. Validation of schizophrenia-associated genes CSMD1, C10orf26, CACNA1C and TCF4 as miR-137 targets. Mol. Psychiatry 2013, 18:11-12.
70. Lewis D.A., Gonzalez-Burgos G. Pathophysiologically based treatment interventions in schizophrenia. Nat. Med. 2006, 12:1016-1022.
71. Malchow B., Hasan A., Fusar-Poli P., Schmitt A., Falkai P., Wobrock T. Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence. Eur. Arch. Psychiatry Clin. Neurosci. 2013, 263:3-13.
72. Malhotra D., Sebat J. CNVs: harbingers of a rare variant revolution in psychiatric genetics. Cell 2012, 148:1223-1241.
73. Marchetto M.C., Winner B., Gage F.H. Pluripotent stem cells in neurodegenerative and neurodevelopmental diseases. Hum. Mol. Genet. 2010, 19:R71-R76.
74. Mata I., Perez-Iglesias R., Roiz-Santianez R., Tordesillas-Gutierrez D., Gonzalez-Mandly A., Berja A., Vazquez-Barquero J.L., Crespo-Facorro B. Additive effect of NRG1 and DISC1 genes on lateral ventricle enlargement in first episode schizophrenia. Neuroimage 2010, 53:1016-1022.
75. Maurano M.T., Humbert R., Rynes E., Thurman R.E., Haugen E., Wang H., Reynolds A.P., Sandstrom R., Qu H., Brody J., Shafer A., Neri F., Lee K., Kutyavin T., Stehling-Sun S., Johnson A.K., Canfield T.K., Giste E., Diegel M., Bates D., Hansen R.S., Neph S., Sabo P.J., Heimfeld S., Raubitschek A., Ziegler S., Cotsapas C., Sotoodehnia N., Glass I., Sunyaev S.R., Kaul R., Stamatoyannopoulos J.A. Systematic localization of common disease-associated variation in regulatory DNA. Science 2012, 337:1190-1195.
76. McCarthy S.E., Makarov V., Kirov G., Addington A.M., McClellan J., Yoon S., Perkins D.O., Dickel D.E., Kusenda M., Krastoshevsky O., Krause V., Kumar R.A., Grozeva D., Malhotra D., Walsh T., Zackai E.H., Kaplan P., Ganesh J., Krantz I.D., Spinner N.B., Roccanova P., Bhandari A., Pavon K., Lakshmi B., Leotta A., Kendall J., Lee Y.H., Vacic V., Gary S., Iakoucheva L.M., Crow T.J., Christian S.L., Lieberman J.A., Stroup T.S., Lehtimaki T., Puura K., Haldeman-Englert C., Pearl J., Goodell M., Willour V.L., Derosse P., Steele J., Kassem L., Wolff J., Chitkara N., McMahon F.J., Malhotra A.K., Potash J.B., Schulze T.G., Nothen M.M., Cichon S., Rietschel M., Leibenluft E., Kustanovich V., Lajonchere C.M., Sutcliffe J.S., Skuse D., Gill M., Gallagher L., Mendell N.R., Craddock N., Owen M.J., O'Donovan M.C., Shaikh T.H., Susser E., Delisi L.E., Sullivan P.F., Deutsch C.K., Rapoport J., Levy D.L., King M.C., Sebat J. Microduplications of 16p11.2 are associated with schizophrenia. Nat. Genet. 2009, 41:1223-1227.
77. McGowan P.O., Sasaki A., D'Alessio A.C., Dymov S., Labonte B., Szyf M., Turecki G., Meaney M.J. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat. Neurosci. 2009, 12:342-348.
78. Michaelson J.J., Shi Y., Gujral M., Zheng H., Malhotra D., Jin X., Jian M., Liu G., Greer D., Bhandari A., Wu W., Corominas R., Peoples A., Koren A., Gore A., Kang S., Lin G.N., Estabillo J., Gadomski T., Singh B., Zhang K., Akshoomoff N., Corsello C., McCarroll S., Iakoucheva L.M., Li Y., Wang J., Sebat J. Whole-genome sequencing in autism identifies hot spots for de novo germline mutation. Cell 2012, 151:1431-1442.
79. Mill J., Caspi A., Williams B.S., Craig I., Taylor A., Polo-Tomas M., Berridge C.W., Poulton R., Moffitt T.E. Prediction of heterogeneity in intelligence and adult prognosis by genetic polymorphisms in the dopamine system among children with attention-deficit/hyperactivity disorder: evidence from 2 birth cohorts. Arch. Gen. Psychiatry 2006, 63:462-469.
80. Moore T.H., Zammit S., Lingford-Hughes A., Barnes T.R., Jones P.B., Burke M., Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007, 370:319-328.
81. Mowry B.J., Gratten J. The emerging spectrum of allelic variation in schizophrenia: current evidence and strategies for the identification and functional characterization of common and rare variants. Mol. Psychiatry 2013, 18:38-52.
82. Mulle J.G., Dodd A.F., McGrath J.A., Wolyniec P.S., Mitchell A.A., Shetty A.C., Sobreira N.L., Valle D., Rudd M.K., Satten G., Cutler D.J., Pulver A.E., Warren S.T. Microdeletions of 3q29 confer high risk for schizophrenia. Am. J. Hum. Genet. 2010, 87:229-236.
83. Myin-Germeys I., Birchwood M., Kwapil T. From environment to therapy in psychosis: a real-world momentary assessment approach. Schizophr. Bull. 2011, 37:244-247.
84. Myin-Germeys I., Oorschot M., Collip D., Lataster J., Delespaul P., van Os J. Experience sampling research in psychopathology: opening the black box of daily life. Psychol. Med. 2009, 39:1533-1547.
85. Need A.C., Ge D., Weale M.E., Maia J., Feng S., Heinzen E.L., Shianna K.V., Yoon W., Kasperaviciute D., Gennarelli M., Strittmatter W.J., Bonvicini C., Rossi G., Jayathilake K., Cola P.A., McEvoy J.P., Keefe R.S., Fisher E.M., St Jean P.L., Giegling I., Hartmann A.M., Moller H.J., Ruppert A., Fraser G., Crombie C., Middleton L.T., St Clair D., Roses A.D., Muglia P., Francks C., Rujescu D., Meltzer H.Y., Goldstein D.B. A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS Genet. 2009, 5:e1000373.
86. Need A.C., McEvoy J.P., Gennarelli M., Heinzen E.L., Ge D., Maia J.M., Shianna K.V., He M., Cirulli E.T., Gumbs C.E., Zhao Q., Campbell C.R., Hong L., Rosenquist P., Putkonen A., Hallikainen T., Repo-Tiihonen E., Tiihonen J., Levy D.L., Meltzer H.Y., Goldstein D.B. Exome sequencing followed by large-scale genotyping suggests a limited role for moderately rare risk factors of strong effect in schizophrenia. Am. J. Hum. Genet. 2012, 91:303-312.
87. Nicodemus K.K., Kolachana B.S., Vakkalanka R., Straub R.E., Giegling I., Egan M.F., Rujescu D., Weinberger D.R. Evidence for statistical epistasis between catechol-O-methyltransferase (COMT) and polymorphisms in RGS4, G72 (DAOA), GRM3, and DISC1: influence on risk of schizophrenia. Hum. Genet. 2007, 120:889-906.
88. Nicodemus K.K., Marenco S., Batten A.J., Vakkalanka R., Egan M.F., Straub R.E., Weinberger D.R. Serious obstetric complications interact with hypoxia-regulated/vascular-expression genes to influence schizophrenia risk. Mol. Psychiatry 2008, 13:873-877.
89. O'Donovan M.C., Craddock N., Norton N., Williams H., Peirce T., Moskvina V., Nikolov I., Hamshere M., Carroll L., Georgieva L., Dwyer S., Holmans P., Marchini J.L., Spencer C.C., Howie B., Leung H.T., Hartmann A.M., Moller H.J., Morris D.W., Shi Y., Feng G., Hoffmann P., Propping P., Vasilescu C., Maier W., Rietschel M., Zammit S., Schumacher J., Quinn E.M., Schulze T.G., Williams N.M., Giegling I., Iwata N., Ikeda M., Darvasi A., Shifman S., He L., Duan J., Sanders A.R., Levinson D.F., Gejman P.V., Cichon S., Nothen M.M., Gill M., Corvin A., Rujescu D., Kirov G., Owen M.J., Buccola N.G., Mowry B.J., Freedman R., Amin F., Black D.W., Silverman J.M., Byerley W.F., Cloninger C.R. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat. Genet. 2008, 40:1053-1055.
90. Oh G., Petronis A. Environmental studies of schizophrenia through the prism of epigenetics. Schizophr. Bull. 2008, 34:1122-1129.
91. Ohnishi T., Hashimoto R., Mori T., Nemoto K., Moriguchi Y., Iida H., Noguchi H., Nakabayashi T., Hori H., Ohmori M., Tsukue R., Anami K., Hirabayashi N., Harada S., Arima K., Saitoh O., Kunugi H. The association between the Val158Met polymorphism of the catechol-O-methyl transferase gene and morphological abnormalities of the brain in chronic schizophrenia. Brain 2006, 129:399-410.
92. Oliver P.L. Challenges of analysing gene-environment interactions in mouse models of schizophrenia. ScientificWorldJournal 2011, 11:1411-1420.
93. Pedersen C.B., Mortensen P.B. Evidence of a dose-response relationship between urbanicity during upbringing and schizophrenia risk. Arch. Gen. Psychiatry 2001, 58:1039-1046.
94. Pedrosa E., Sandler V., Shah A., Carroll R., Chang C., Rockowitz S., Guo X., Zheng D., Lachman H.M. Development of patient-specific neurons in schizophrenia using induced pluripotent stem cells. J. Neurogenet. 2011, 25:88-103.
95. Purcell S.M., Wray N.R., Stone J.L., Visscher P.M., O'Donovan M.C., Sullivan P.F., Sklar P. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460:748-752.
96. Quednow B.B., Ettinger U., Mossner R., Rujescu D., Giegling I., Collier D.A., Schmechtig A., Kuhn K.U., Moller H.J., Maier W., Wagner M., Kumari V. The schizophrenia risk allele C of the TCF4 rs9960767 polymorphism disrupts sensorimotor gating in schizophrenia spectrum and healthy volunteers. J. Neurosci. 2011, 31:6684-6691.
97. Rabin R.A., Zakzanis K.K., George T.P. The effects of cannabis use on neurocognition in schizophrenia: a meta-analysis. Schizophr. Res. 2011, 128:111-116.
98. Rees E., Kirov G., O'Donovan M.C., Owen M.J. De novo mutation in schizophrenia. Schizophr. Bull. 2012, 38:377-381.
99. Rethelyi J.M., Bakker S.C., Polgar P., Czobor P., Strengman E., Pasztor P.I., Kahn R.S., Bitter I. Association study of NRG1, DTNBP1, RGS4, G72/G30, and PIP5K2A with schizophrenia and symptom severity in a Hungarian sample. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2010, 153B:792-801.
100. Ripke S., Sanders A.R., Kendler K.S., Levinson D.F., Sklar P., Holmans P.A., Lin D.Y., Duan J., Ophoff R.A., Andreassen O.A., Scolnick E., Cichon S., St Clair D., Corvin A., Gurling H., Werge T., Rujescu D., Blackwood D.H., Pato C.N., Malhotra A.K., Purcell S., Dudbridge F., Neale B.M., Rossin L., Visscher P.M., Posthuma D., Ruderfer D.M., Fanous A., Stefansson H., Steinberg S., Mowry B.J., Golimbet V., De Hert M., Jonsson E.G., Bitter I., Pietilainen O.P., Collier D.A., Tosato S., Agartz I., Albus M., Alexander M., Amdur R.L., Amin F., Bass N., Bergen S.E., Black D.W., Borglum A.D., Brown M.A., Bruggeman R., Buccola N.G., Byerley W.F., Cahn W., Cantor R.M., Carr V.J., Catts S.V., Choudhury K., Cloninger C.R., Cormican P., Craddock N., Danoy P.A., Datta S., de Haan L., Demontis D., Dikeos D., Djurovic S., Donnelly P., Donohoe G., Duong L., Dwyer S., Fink-Jensen A., Freedman R., Freimer N.B., Friedl M., Georgieva L., Giegling I., Gill M., Glenthoj B., Godard S., Hamshere M., Hansen M., Hansen T., Hartmann A.M., Henskens F.A., Hougaard D.M., Hultman C.M., Ingason A., Jablensky A.V., Jakobsen K.D., Jay M., Jurgens G., Kahn R.S., Keller M.C., Kenis G., Kenny E., Kim Y., Kirov G.K., Konnerth H., Konte B., Krabbendam L., Krasucki R., Lasseter V.K., Laurent C., Lawrence J., Lencz T., Lerer F.B., Liang K.Y., Lichtenstein P., Lieberman J.A., Linszen D.H., Lonnqvist J., Loughland C.M., Maclean A.W., Maher B.S., Maier W., Mallet J., Malloy P., Mattheisen M., Mattingsdal M., McGhee K.A., McGrath J.J., McIntosh A., McLean D.E., McQuillin A., Melle I., Michie P.T., Milanova V., Morris D.W., Mors O., Mortensen P.B., Moskvina V., Muglia P., Myin-Germeys I., Nertney D.A., Nestadt G., Nielsen J., Nikolov I., Nordentoft M., Norton N., Nothen M.M., O'Dushlaine C.T., Olincy A., Olsen L., O'Neill F.A., Orntoft T.F., Owen M.J., Pantelis C., Papadimitriou G., Pato M.T., Peltonen L., Petursson H., Pickard B., Pimm J., Pulver A.E., Puri V., Quested D., Quinn E.M., Rasmussen H.B., Rethelyi J.M., Ribble R., Rietschel M., Riley B.P., Ruggeri M., Schall U., Schulze T.G., Schwab S.G., Scott R.J., Shi J., Sigurdsson E., Silverman J.M., Spencer C.C., Stefansson K., Strange A., Strengman E., Stroup T.S., Suvisaari J., Terenius L., Thirumalai S., Thygesen J.H., Timm S., Toncheva D., van den Oord E., van Os J., van Winkel R., Veldink J., Walsh D., Wang A.G., Wiersma D., Wildenauer D.B., Williams H.J., Williams N.M., Wormley B., Zammit S., Sullivan P.F., O'Donovan M.C., Daly M.J., Gejman P.V. Genome-wide association study identifies five new schizophrenia loci. Nat. Genet. 2011, 43:969-976.
101. Ross C.A., Margolis R.L., Reading S.A., Pletnikov M., Coyle J.T. Neurobiology of schizophrenia. Neuron 2006, 52:139-153.
102. Rujescu D., Ingason A., Cichon S., Pietilainen O.P., Barnes M.R., Toulopoulou T., Picchioni M., Vassos E., Ettinger U., Bramon E., Murray R., Ruggeri M., Tosato S., Bonetto C., Steinberg S., Sigurdsson E., Sigmundsson T., Petursson H., Gylfason A., Olason P.I., Hardarsson G., Jonsdottir G.A., Gustafsson O., Fossdal R., Giegling I., Moller H.J., Hartmann A.M., Hoffmann P., Crombie C., Fraser G., Walker N., Lonnqvist J., Suvisaari J., Tuulio-Henriksson A., Djurovic S., Melle I., Andreassen O.A., Hansen T., Werge T., Kiemeney L.A., Franke B., Veltman J., Buizer-Voskamp J.E., Sabatti C., Ophoff R.A., Rietschel M., Nothen M.M., Stefansson K., Peltonen L., St Clair D., Stefansson H., Collier D.A. Disruption of the neurexin 1 gene is associated with schizophrenia. Hum. Mol. Genet. 2009, 18:988-996.
103. Sebat J., Levy D.L., McCarthy S.E. Rare structural variants in schizophrenia: one disorder, multiple mutations: one mutation, multiple disorders. Trends Genet. 2009, 25:528-535.
104. Selten J.P., Cantor-Graae E. Social defeat: risk factor for schizophrenia?. Br. J. Psychiatry 2005, 187:101-102.
105. Shatz C.J. MHC class I: an unexpected role in neuronal plasticity. Neuron 2009, 64:40-45.
106. Shi, J., Levinson, D.F., Duan, J., Sanders, A.R., Zheng, Y., Pe'er, I., Dudbridge, F., Holmans, P.A., Whittemore, A.S., Mowry, B.J., Olincy, A., Amin, F., Cloninger, C.R., Silverman, J.M., Buccola, N.G., Byerley, W.F., Black, D.W., Crowe, R.R., Oksenberg, J.R., Mirel, D.B., Kendler, K.S., Freedman, R., Gejman, P.V., 2009. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 460, 753-757.
107. Stefansson H., Ophoff R.A., Steinberg S., Andreassen O.A., Cichon S., Rujescu D., Werge T., Pietilainen O.P., Mors O., Mortensen P.B., Sigurdsson E., Gustafsson O., Nyegaard M., Tuulio-Henriksson A., Ingason A., Hansen T., Suvisaari J., Lonnqvist J., Paunio T., Borglum A.D., Hartmann A., Fink-Jensen A., Nordentoft M., Hougaard D., Norgaard-Pedersen B., Bottcher Y., Olesen J., Breuer R., Moller H.J., Giegling I., Rasmussen H.B., Timm S., Mattheisen M., Bitter I., Rethelyi J.M., Magnusdottir B.B., Sigmundsson T., Olason P., Masson G., Gulcher J.R., Haraldsson M., Fossdal R., Thorgeirsson T.E., Thorsteinsdottir U., Ruggeri M., Tosato S., Franke B., Strengman E., Kiemeney L.A., Melle I., Djurovic S., Abramova L., Kaleda V., Sanjuan J., de Frutos R., Bramon E., Vassos E., Fraser G., Ettinger U., Picchioni M., Walker N., Toulopoulou T., Need A.C., Ge D., Yoon J.L., Shianna K.V., Freimer N.B., Cantor R.M., Murray R., Kong A., Golimbet V., Carracedo A., Arango C., Costas J., Jonsson E.G., Terenius L., Agartz I., Petursson H., Nothen M.M., Rietschel M., Matthews P.M., Muglia P., Peltonen L., St Clair D., Goldstein D.B., Stefansson K., Collier D.A. Common variants conferring risk of schizophrenia. Nature 2009, 460:744-747.
108. Stefansson H., Rujescu D., Cichon S., Pietilainen O.P., Ingason A., Steinberg S., Fossdal R., Sigurdsson E., Sigmundsson T., Buizer-Voskamp J.E., Hansen T., Jakobsen K.D., Muglia P., Francks C., Matthews P.M., Gylfason A., Halldorsson B.V., Gudbjartsson D., Thorgeirsson T.E., Sigurdsson A., Jonasdottir A., Bjornsson A., Mattiasdottir S., Blondal T., Haraldsson M., Magnusdottir B.B., Giegling I., Moller H.J., Hartmann A., Shianna K.V., Ge D., Need A.C., Crombie C., Fraser G., Walker N., Lonnqvist J., Suvisaari J., Tuulio-Henriksson A., Paunio T., Toulopoulou T., Bramon E., Di Forti M., Murray R., Ruggeri M., Vassos E., Tosato S., Walshe M., Li T., Vasilescu C., Muhleisen T.W., Wang A.G., Ullum H., Djurovic S., Melle I., Olesen J., Kiemeney L.A., Franke B., Sabatti C., Freimer N.B., Gulcher J.R., Thorsteinsdottir U., Kong A., Andreassen O.A., Ophoff R.A., Georgi A., Rietschel M., Werge T., Petursson H., Goldstein D.B., Nothen M.M., Peltonen L., Collier D.A., St Clair D., Stefansson K. Large recurrent microdeletions associated with schizophrenia. Nature 2008, 455:232-236.
109. Steinberg S., de Jong S., Andreassen O.A., Werge T., Borglum A.D., Mors O., Mortensen P.B., Gustafsson O., Costas J., Pietilainen O.P., Demontis D., Papiol S., Huttenlocher J., Mattheisen M., Breuer R., Vassos E., Giegling I., Fraser G., Walker N., Tuulio-Henriksson A., Suvisaari J., Lonnqvist J., Paunio T., Agartz I., Melle I., Djurovic S., Strengman E., Jurgens G., Glenthoj B., Terenius L., Hougaard D.M., Orntoft T., Wiuf C., Didriksen M., Hollegaard M.V., Nordentoft M., van Winkel R., Kenis G., Abramova L., Kaleda V., Arrojo M., Sanjuan J., Arango C., Sperling S., Rossner M., Ribolsi M., Magni V., Siracusano A., Christiansen C., Kiemeney L.A., Veldink J., van den Berg L., Ingason A., Muglia P., Murray R., Nothen M.M., Sigurdsson E., Petursson H., Thorsteinsdottir U., Kong A., Rubino I.A., De Hert M., Rethelyi J.M., Bitter I., Jonsson E.G., Golimbet V., Carracedo A., Ehrenreich H., Craddock N., Owen M.J., O'Donovan M.C., Ruggeri M., Tosato S., Peltonen L., Ophoff R.A., Collier D.A., St Clair D., Rietschel M., Cichon S., Stefansson H., Rujescu D., Stefansson K. Common Variants at VRK2 and TCF4 Conferring Risk of Schizophrenia. Hum. Mol. Genet. 2011, 20:4076-4081.
110. Steinberg S., Mors O., Borglum A.D., Gustafsson O., Werge T., Mortensen P.B., Andreassen O.A., Sigurdsson E., Thorgeirsson T.E., Bottcher Y., Olason P., Ophoff R.A., Cichon S., Gudjonsdottir I.H., Pietilainen O.P., Nyegaard M., Tuulio-Henriksson A., Ingason A., Hansen T., Athanasiu L., Suvisaari J., Lonnqvist J., Paunio T., Hartmann A., Jurgens G., Nordentoft M., Hougaard D., Norgaard-Pedersen B., Breuer R., Moller H.J., Giegling I., Glenthoj B., Rasmussen H.B., Mattheisen M., Bitter I., Rethelyi J.M., Sigmundsson T., Fossdal R., Thorsteinsdottir U., Ruggeri M., Tosato S., Strengman E., Kiemeney L.A., Melle I., Djurovic S., Abramova L., Kaleda V., Walshe M., Bramon E., Vassos E., Li T., Fraser G., Walker N., Toulopoulou T., Yoon J., Freimer N.B., Cantor R.M., Murray R., Kong A., Golimbet V., Jonsson E.G., Terenius L., Agartz I., Petursson H., Nothen M.M., Rietschel M., Peltonen L., Rujescu D., Collier D.A., Stefansson H., St Clair D., Stefansson K. Expanding the range of ZNF804A variants conferring risk of psychosis. Mol. Psychiatry 2011, 16:59-66.
111. Sullivan P.F., Kendler K.S., Neale M.C. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch. Gen. Psychiatry 2003, 60:1187-1192.
112. Terwisscha van Scheltinga A., Bakker S., van Haren N., Buizer-Voskamp J., Boos H., Vorstman J., Cahn W., Hulshoff Pol H., Ophoff R., Kahn R. Association study of copy number variants with brain volume in schizophrenia patients and healthy controls. Psychiatry Res. 2012, 200:1011-1013.
113. Terwisscha van Scheltinga A.F., Bakker S.C., van Haren N.E., Derks E.M., Buizer-Voskamp J.E., Boos H.B., Cahn W., Hulshoff Pol H.E., Ripke S., Ophoff R.A., Kahn R.S. Genetic schizophrenia risk variants jointly modulate total brain and white matter volume. Biol. Psychiatry 2013, 73:525-531.
114. Thiselton D.L., Vladimirov V.I., Kuo P.H., McClay J., Wormley B., Fanous A., O'Neill F.A., Walsh D., Van den Oord E.J., Kendler K.S., Riley B.P. AKT1 is associated with schizophrenia across multiple symptom dimensions in the Irish study of high density schizophrenia families. Biol. Psychiatry 2008, 63:449-457.
115. Tosato S., Bellani M., Bonetto C., Ruggeri M., Perlini C., Lasalvia A., Marinelli V., Rambaldelli G., Cristofalo D., Bertani M., Zanoni M., Lazzarotto L., Cerini R., Pozzi Mucelli R., Tansella M., Dazzan P., Di Forti M., Murray R.M., Collier D.A., Brambilla P. Is neuregulin 1 involved in determining cerebral volumes in schizophrenia? Preliminary results showing a decrease in superior temporal gyrus volume. Neuropsychobiology 2012, 65:119-125.
116. van Os J., Hanssen M., Bak M., Bijl R.V., Vollebergh W. Do urbanicity and familial liability coparticipate in causing psychosis?. Am. J. Psychiatry 2003, 160:477-482.
117. van Os J., Kapur S. Schizophrenia. Lancet 2009, 374:635-645.
118. van Os J., Kenis G., Rutten B.P. The environment and schizophrenia. Nature 2010, 468:203-212.
119. van Os J., Pedersen C.B., Mortensen P.B. Confirmation of synergy between urbanicity and familial liability in the causation of psychosis. Am. J. Psychiatry 2004, 161:2312-2314.
120. van Os J., Rutten B.P. Gene-environment-wide interaction studies in psychiatry. Am. J. Psychiatry 2009, 166:964-966.
121. van Os J., Rutten B.P., Poulton R. Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions. Schizophr. Bull. 2008, 34:1066-1082.
122. Van Winkel R., Esquivel G., Kenis G. Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. Arch. Gen. Psychiatry 2011, 68:148-157. Genetic Risk and Outcome of Psychosis (GROUP) Investigators.
123. Van Winkel R., Esquivel G., Kenis G., Wichers M., Collip D., Peerbooms O., Rutten B., Myin-Germeys I., Van Os J. Review: Genome-wide findings in schizophrenia and the role of gene-environment interplay. CNS Neurosci. Ther. 2010, 16:e185-e192.
124. Van Winkel R., Henquet C., Rosa A., Papiol S., Fananas L., De Hert M., Peuskens J., Van Os J., Myin-Germeys I. Evidence that the COMT(Val158Met) polymorphism moderates sensitivity to stress in psychosis: an experience-sampling study. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2008, 147B:10-17.
125. van Winkel R., Stefanis N.C., Myin-Germeys I. Psychosocial stress and psychosis. A review of the neurobiological mechanisms and the evidence for gene-stress interaction. Schizophr. Bull. 2008, 34:1095-1105.
126. van Winkel, R., van Beveren, N.J., Simons, C.R.S., Linszen, D.H., Van Os, J., Wiersma, D., Bruggeman, R., Cahn, W., de Haan, L., Krabbendam, L., Myin-Germeys, I., 2011b. AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder. Neuropsychopharmacology, 36, 2529-2537.
127. van Zelst C. Which environments for G x E? A user perspective on the roles of trauma and structural discrimination in the onset and course of schizophrenia. Schizophr. Bull. 2008, 34:1106-1110.
128. van Zelst C. Stigma and schizophrenia. Lancet 2009, 373:1336. (author reply 1336-1337).
129. van Zelst C. Stigmatization as an environmental risk in schizophrenia: a user perspective. Schizophr. Bull. 2009, 35:293-296.
130. Varese F., Smeets F., Drukker M., Lieverse R., Lataster T., Viechtbauer W., Read J., van Os J., Bentall R.P. Childhood adversities increase the risk of psychosis: a meta-analysis of patient-control, prospective- and cross-sectional cohort studies. Schizophr. Bull. 2012, 38:661-671.
131. Vrijenhoek T., Buizer-Voskamp J.E., van der Stelt I., Strengman E., Sabatti C., Geurts van Kessel A., Brunner H.G., Ophoff R.A., Veltman J.A. Recurrent CNVs disrupt three candidate genes in schizophrenia patients. Am. J. Hum. Genet. 2008, 83:504-510.
132. Walters J.T., Corvin A., Owen M.J., Williams H., Dragovic M., Quinn E.M., Judge R., Smith D.J., Norton N., Giegling I., Hartmann A.M., Moller H.J., Muglia P., Moskvina V., Dwyer S., O'Donoghue T., Morar B., Cooper M., Chandler D., Jablensky A., Gill M., Kaladjieva L., Morris D.W., O'Donovan M.C., Rujescu D., Donohoe G. Psychosis susceptibility gene ZNF804A and cognitive performance in schizophrenia. Arch. Gen. Psychiatry 2010, 67:692-700.
133. Weiser M., van Os J., Reichenberg A., Rabinowitz J., Nahon D., Kravitz E., Lubin G., Shmushkevitz M., Knobler H.Y., Noy S., Davidson M. Social and cognitive functioning, urbanicity and risk for schizophrenia. Br. J. Psychiatry 2007, 191:320-324.
134. Weiser M., Werbeloff N., Vishna T., Yoffe R., Lubin G., Shmushkevitch M., Davidson M. Elaboration on immigration and risk for schizophrenia. Psychol. Med. 2008, 38:1113-1119.
135. Wigman J.T., van Winkel R., Ormel J., Verhulst F.C., van Os J., Vollebergh W.A. Early trauma and familial risk in the development of the extended psychosis phenotype in adolescence. Acta Psychiatr. Scand. 2012, 126:266-273.
136. Wittchen H.U., Jacobi F., Rehm J., Gustavsson A., Svensson M., Jonsson B., Olesen J., Allgulander C., Alonso J., Faravelli C., Fratiglioni L., Jennum P., Lieb R., Maercker A., van Os J., Preisig M., Salvador-Carulla L., Simon R., Steinhausen H.C. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol. 2011, 21:655-679.
137. Wong C.C., Caspi A., Williams B., Craig I.W., Houts R., Ambler A., Moffitt T.E., Mill J. A longitudinal study of epigenetic variation in twins. Epigenetics 2010, 5:516-526.
138. Xu B., Ionita-Laza I., Roos J.L., Boone B., Woodrick S., Sun Y., Levy S., Gogos J.A., Karayiorgou M. De novo gene mutations highlight patterns of genetic and neural complexity in schizophrenia. Nat. Genet. 2012, 44:1365-1369.
139. Xu B., Roos J.L., Dexheimer P., Boone B., Plummer B., Levy S., Gogos J.A., Karayiorgou M. Exome sequencing supports a de novo mutational paradigm for schizophrenia. Nat. Genet. 2011, 43:864-868.
140. Yamanaka S. Induced pluripotent stem cells: past, present, and future. Cell Stem Cell 2012, 10:678-684.
141. Yu C.C., Furukawa M., Kobayashi K., Shikishima C., Cha P.C., Sese J., Sugawara H., Iwamoto K., Kato T., Ando J., Toda T. Genome-wide DNA methylation and gene expression analyses of monozygotic twins discordant for intelligence levels. PLoS ONE 2012, 7:e47081.
142. Zammit S., Owen M.J., Evans J., Heron J., Lewis G. Cannabis, COMT and psychotic experiences. Br. J. Psychiatry 2011, 199:380-385.
143. Zammit S., Owen M.J., Lewis G. Misconceptions about gene-environment interactions in psychiatry. Evid. Based Ment. Health 2010, 13:65-68.
144. Zammit S., Spurlock G., Williams H., Norton N., Williams N., O'Donovan M.C., Owen M.J. Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. Br. J. Psychiatry 2007, 191:402-407.
145. Zammit S., Wiles N.J., Lewis G. The study of gene-environment interactions in psychiatry: limited gains at a substantial cost?. Psychol. Med. 2010, 40:711-716.
146. Zhu H., Lensch M.W., Cahan P., Daley G.Q. Investigating monogenic and complex diseases with pluripotent stem cells. Nat. Rev. Genet. 2011, 12:266-275.
147. Zhu X., Gu H., Liu Z., Xu Z., Chen X., Sun X., Zhai J., Zhang Q., Chen M., Wang K., Deng X., Ji F., Liu C., Li J., Dong Q., Chen C. Associations between TCF4 gene polymorphism and cognitive functions in schizophrenia patients and healthy controls. Neuropsychopharmacology 2013, 38:683-689.
148. Zubin J., Spring B. Vulnerability-a new view of schizophrenia. J. Abnorm. Psychol. 1977, 86:103-126.